-
Drug release: The FDA expert team supports the retention of T drugs for the first-line treatment of mTNBC with 7:2
Time of Update: 2021-05-08
Based on data from a clinical study called IMpassion130, in March 2019, the FDA accelerated the approval of Tecentriq combined with Abraxane (albumin paclitaxel) for the first-line treatment of PD-L1-positive advanced or metastatic triple-negative breast cancer patients, which is also used The first immunotherapy for breast cancer treatment.
-
elife: The amino acids in the diet determine the fate of cancer cells
Time of Update: 2021-05-08
This phenomenon is considered Is a "fail safe" mechanismThe international research team led by Sa Kan Yoo focused on the tumor gene Src.
-
Express | For the treatment of non-small cell lung cancer, Takeda's potential "first-in-class" therapy receives FDA priority review
Time of Update: 2021-05-08
S. FDA has granted priority review status for its new drug application for mobocertinib (TAK-788) for the treatment of metastatic EGFR exon 20 insertion Adult patients with non-small cell lung cancer (NSCLC).
-
Hepatobiliary Surg Nutr: Gene mutation characteristics of Chinese liver cancer patients!
Time of Update: 2021-05-08
The most common mutant genes are TP53, TERT, CTNNB1, AXIN1, RB1, TSC2, CCND1, ARID1A, and FGF19Compared to wild type patients, patients carrying mutations in TP53 Edmondson III-IV stage and a micro- vessel ratio infiltration significantly higher (p <0.
The most common mutated genes in Chinese HCC patients are TP53, TERT and CTNNB1.
-
Lancet Oncol: Intensive chemotherapy before preoperative radiotherapy and chemotherapy for patients with advanced rectal cancer can further significantly improve the prognosis of patients
Time of Update: 2021-05-08
Myocardial infarctionIn summary, for patients with cT3 or cT4 M0 stage rectal cancer, FOLFIRINOX intensive chemotherapy before preoperative radiotherapy can significantly improve their survival prognosis.
For patients with cT3 or cT4 M0 stage rectal cancer, FOLFIRINOX intensive chemotherapy before preoperative radiotherapy can significantly improve their survival prognosis.
-
2021 CSCO Guidelines Update | Leukemia Update Key Points
Time of Update: 2021-05-08
Relapsed and refractory patients have indications for treatment, no del(17p)/TP53 gene mutations, and no matter whether there is a serious concomitant disease (CIRS score> 6 points), the level I recommendation is to add "Ibrutinib, Zebutinib, Obu" Tinib, Venecla + Rituximab/Otuzumab".
-
Eur Radiol: How to evaluate whether there is infiltration at the margin during radical prostatectomy?
Time of Update: 2021-05-08
Recently, a study published in the journal European Radiology established and validated a simple MRI-based model to determine the risk of positive surgical margins (PSMs) in patients with prostate cancer (PCa) undergoing radical prostatectomy (RP).
-
Behind the craze, immune cell therapy is challenging from R&D to production and quality control.
Time of Update: 2021-05-08
For example, in non-clinical research, the pharmacological characterization of immune cell therapy is special; in terms of production process, the preparation process is immature, the cost is high, and the yield is small; in terms of quality control, the starting material varies greatly, and the evaluation of efficacy and safety is complicated Difficulties that need to be overcome.
-
J Clin Oncol: Patients with advanced ovarian cancer should not be treated with immune checkpoint inhibitors!
Time of Update: 2021-05-08
To evaluate the addition of human monoclonal anti-PD-L1 antibody atezolizumab to newly diagnosed stage III-IV ovarian cancer in the platinum-based combination with bevacizumab EfficacyThis is a multicenter, placebo-controlled, randomized, double-blind phase III trial that recruited newly diagnosed patients with stage III-IV ovarian cancer who had undergone primary tumor cytoreduction or planned to undergo Neoadjuvant chemotherapy and interval surgery.
-
ESMO Open: Is Axitinib harmful to renal cell carcinoma?
Time of Update: 2021-05-08
100105" target="_blank" rel="noopener">ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups .
100105" target="_blank" rel="noopener">ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups in this message
-
Radiology: For breast cancer patients with simple bone metastases, whole-body MRI imaging can do more
Time of Update: 2021-05-08
This study shows that in most patients with breast cancer with simple bone metastases, whole-body MRI can identify progressive disease (PD) before CT.
This study shows that in most patients with breast cancer with simple bone metastases, whole-body MRI can identify progressive disease (PD) before CT.
-
Lancet Oncol: The effect of long-term maintenance treatment with olaparib on the quality of life of patients
Time of Update: 2021-05-08
In the Phase 3 SOLO1 trial, olaparib maintenance treatment provided newly diagnosed BRCA mutations in patients with advanced ovarian cancer who had remission after platinum-based chemotherapy and provided significantly longer progression-free survival than the placebo group.
-
"The Lancet·Tumor": The team from Zhongshan Hospital of Fudan University has made great achievements. The second tumor reduction surgery can reduce the risk of disease progression or death in patients with platinum-sensitive recurrent ovarian cancer by 42%|Clinical Discovery
Time of Update: 2021-05-08
They found that in patients with platinum-sensitive recurrent ovarian cancer, chemotherapy and only treatment were performed after the second cytoreduction.
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.
-
Yang Lin Comments | A rising star in cancer immunotherapy-γδ T cells
Time of Update: 2021-05-08
Although major breakthroughs have been made in current immunotherapy, CAR-T cell therapy based on αβ T cells is limited in the treatment of solid tumors and the use of allogenes.
-
Amgen's innovative first-line therapy for gastric cancer, bemarituzumab, is recognized by the U.S. FDA as a breakthrough therapy
Time of Update: 2021-05-08
bemarituzumab is a first-in-class targeting antibody developed by Five Prime Therapeutics, which prevents FGF from binding and activating FGFR2b, inhibits a variety of downstream pro-tumor signaling pathways, and may delay cancer progression.
-
Albumin paclitaxel can be used as the standard treatment option for patients with advanced NSCLC; PD-1/CTLA-4 dual antibody was approved to carry out a phase III clinical trial for the first-line treatment of advanced cervical cancer|Tumor News
Time of Update: 2021-05-08
(If you need the original text of the literature, you can add the editor WeChat yxj_oncology to obtain) Key points: JTO: After treatment of advanced NSCLC, the OS of albumin paclitaxel treatment is not inferior to docetaxel Lancet Gastroenterol Hepatol: LSD can safely and effectively treat the pancreas or ampulla Peripheral Tumor Gastroenterology: Gene and epigenetic characteristics of inflammatory bowel disease-related colorectal cancer.
-
Nat Med: Gene therapy research should always focus on co-management, sharing and progress
Time of Update: 2021-05-08
In order to fully understand and reduce the risk of delayed adverse events, participants in gene therapy trials will need to be monitored for a longer period of time-often referred to as the "long-term follow-up" period of clinical studies.
-
Lancet Oncol: Long-term (15 years) prognosis of early breast cancer with a single intraoperative radiotherapy
Time of Update: 2021-05-08
Previous randomized phase 3 equivalent trials on intraoperative electronic beam radiotherapy (ELIOT) showed that for patients with early breast cancer, compared with whole breast radiotherapy (WBI), the use of intraoperative radiotherapy for accelerated local breast radiotherapy (APBI) and ipsilateral breast Tumor recurrence rate (IBTR) is higher correlated .
-
Health Commission: The 5-year survival rate of malignant tumors in China has increased by nearly 10%
Time of Update: 2021-05-08
Jiao Yahui, director of the National Health Commission’s Medical Administration and Hospital Administration Bureau, pointed out on the 27th that with the improvement of my country’s medical quality and diagnosis and treatment capabilities, the five-year survival rate for malignant tumors has increased from 30.
-
Lancet oncol: Comparison of the efficacy of multiple radiotherapy and chemotherapy combinations in the treatment of locally advanced head and neck cancer
Time of Update: 2021-05-08
Compared with CLRTP (P score 78%), the other three treatments have higher overall survival rate P score, but HR has not improved significantlyIn summary, the results of this network meta-analysis show that the use of HFCRT or ICTaxPF-CLRT to further strengthen radiotherapy and chemotherapy is more effective than radiotherapy for locally advanced head and neck cancer .
